Close

SunTrust Assumes uniQure BV (QURE) at Buy

December 20, 2019 7:51 AM EST
Get Alerts QURE Hot Sheet
Price: $5.32 -1.66%

Rating Summary:
    23 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 10 | New: 11
Join SI Premium – FREE

SunTrust analyst Robyn Karnauskas assumes coverage on uniQure BV (NASDAQ: QURE) with a Buy rating and a price target of $90.00.

The analyst commented, "QURE is a gene therapy platform company supported by strong science, leading manufacturing, and experienced management. We believe QURE could potentially have both first- and best-in-class gene therapy options in both hemophilia B (EtranaDeZ) and Huntington's disease (AMT-130)."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $69.99 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage